Therapy to target renal cell carcinoma using  131 I-labeled B7-H3 monoclonal antibody

Gongcheng Wang; Ziyu Wu; Yunyan Wang; Xueqin Li; Guangbo Zhang; Jianquan Hou

doi:10.18632/oncotarget.8550

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Therapy to target renal cell carcinoma using ¹³¹I-labeled B7-H3 monoclonal antibody

Gongcheng Wang, Ziyu Wu, Yunyan Wang, Xueqin Li, Guangbo Zhang and Jianquan Hou _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:24888-24898. https://doi.org/10.18632/oncotarget.8550

Metrics: PDF 2061 views | HTML 1984 views | ?

Abstract

Gongcheng Wang1,*, Ziyu Wu2,*, Yunyan Wang1,*, Xueqin Li3, Guangbo Zhang4 and Jianquan Hou5

1 Department of Urology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu, China

2 Department of Urology, Huai’an Hospital Affiliated of Xuzhou Medical College and Huai’an Second People’s Hospital, Huai’an, Jiangsu, China

3 Department of Gerontology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu, China

4 Department of Clinical Immunology Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

5 Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

* These authors have contributed equally to this work

Correspondence to:

Jianquan Hou, email:

Keywords: B7-H3; mice, nude; renal cell carcinoma; targeting therapy; monoclonal antibody

Received: July 19, 2015 Accepted: March 18, 2016 Published: April 02, 2016

Abstract

B7-H3 is a tumor-associated antigen that plays a critical role in potential tumor-targeted therapy. In this study, we aimed to assess the radiobiological effect of 131I-labeled B7-H3 monoclonal antibody (131I-4H7) in nude mice with human renal cell carcinoma (RCC) and evaluate the effect of 131I-4H7 on RCC treatment. The radiobiological activity and tumor uptake of 131I-4H7, and its effect on tumor growth were measured. 131I-4H7 was absorbed by the tumor and reached its maximal uptake rate (3.32% injected dose [ID]/g) at 24 h, at which point the drug concentration in the tumor was 7.36-, 2.06-, 1.80-, and 2.78-fold higher than that in muscle, kidneys, liver, and heart, respectively. Measurements and positron emission tomography–computed tomography imaging showed that tumor development was significantly inhibited by 131I-4H7. HE staining revealed that 131I-4H7 significantly injures tumor cells. Our results suggest that 131I-4H7 is markedly absorbed by the tumor and did suppress the development of RCC xenografted tumors in nude mice, which might provide a new candidate for antibody-mediated targeted radiotherapy in human RCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8550

Publication Alerts

Clinical Research Papers:

Therapy to target renal cell carcinoma using 131I-labeled B7-H3 monoclonal antibody

Abstract

Therapy to target renal cell carcinoma using ¹³¹I-labeled B7-H3 monoclonal antibody